News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
PRASAD SUYASH
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/07/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/08/2022 |
4
| PRASAD SUYASH (CMO and Head of R&D) has filed a Form 4 on Taysha Gene Therapies, Inc.|
Txns:
| Granted 40,325 options to buy
@ $6.52, valued at
$262.9k
|
|
| 02/25/2022 |
4
| PRASAD SUYASH (CMO and Head of R&D) has filed a Form 4 on Taysha Gene Therapies, Inc.|
Txns:
| Granted 80,650 options to buy
@ $5.96, valued at
$480.7k
|
|
| 07/01/2021 |
4
| PRASAD SUYASH (CMO and Head of R&D) has filed a Form 4 on Taysha Gene Therapies, Inc.|
Txns:
| Sold 35,056 shares
@ $23.74, valued at
$832.2k
Sold 3,862 shares
@ $24.46, valued at
$94.5k
Sold 300 shares
@ $25.19, valued at
$7.6k
Sold 13,374 shares
@ $21.42, valued at
$286.5k
Sold 6,202 shares
@ $22.44, valued at
$139.2k
Sold 500 shares
@ $23.7, valued at
$11.9k
Sold 19,706 shares
@ $21.12, valued at
$416.2k
|
|
| 01/20/2021 |
4
| PRASAD SUYASH (CMO and Head of R&D) has filed a Form 4 on Taysha Gene Therapies, Inc.|
Txns:
| Granted 80,000 options to buy
@ $31, valued at
$2.5M
|
|
| 09/30/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/25/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/23/2020 |
3
| PRASAD SUYASH (CMO and Head of R&D) has filed a Form 3 on Taysha Gene Therapies, Inc. |
| 06/07/2019 |
4
| PRASAD SUYASH (Senior VP & Chief Med Officer) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 757 shares
@ $37.31, valued at
$28.2k
|
|
| 05/15/2019 |
4
| PRASAD SUYASH (Senior VP & Chief Med Officer) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Sold 9,946 shares
@ $36.9758, valued at
$367.8k
Sold 54 shares
@ $37.72, valued at
$2k
Exercised 10,000 options to buy
@ $0.79, valued at
$7.9k
|
|
| 02/27/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/08/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/16/2018 |
4
| PRASAD SUYASH (Senior VP & Chief Med Officer) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Granted 736 shares
@ $19.635, valued at
$14.5k
|
|
| 10/02/2018 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/05/2018 |
4
| PRASAD SUYASH (Senior VP & Chief Med Officer) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Sold 4,989 shares
@ $38.0244, valued at
$189.7k
Sold 5,011 shares
@ $38.7874, valued at
$194.4k
Exercised 4,989 options to buy
@ $0.79, valued at
$3.9k
Exercised 5,011 options to buy
@ $0.79, valued at
$4k
|
|
| 03/29/2018 |
4
| PRASAD SUYASH (Senior VP & Chief Med Officer) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Sold 7,800 shares
@ $30.025, valued at
$234.2k
Exercised 7,800 options to buy
@ $0.79, valued at
$6.2k
|
|
| 03/28/2018 |
4
| PRASAD SUYASH (Senior VP & Chief Med Officer) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Sold 1,900 shares
@ $30, valued at
$57k
Sold 300 shares
@ $30, valued at
$9k
Exercised 1,900 options to buy
@ $0.79, valued at
$1.5k
Exercised 300 options to buy
@ $0.79, valued at
$237 |
|
| 12/05/2017 |
4
| PRASAD SUYASH (Senior VP & Chief Med Officer) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Sold 6,770 shares
@ $28.451, valued at
$192.6k
Sold 1,230 shares
@ $28.9842, valued at
$35.7k
Exercised 8,000 options to buy
@ $0.79, valued at
$6.3k
|
|
| 11/17/2017 |
4
| PRASAD SUYASH (Senior VP & Chief Med Officer) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Granted 75,000 options to buy
@ $27.39, valued at
$2.1M
|
|
| 09/01/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/27/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 07/19/2016 |
3
| PRASAD SUYASH (Senior VP & Chief Med Officer) has filed a Form 3 on Audentes Therapeutics, Inc. |
|
|